Gajanan Sapkal

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 433 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +6

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella, Siddharth Reddy, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 360 citations · Full text

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Raches Ella, Siddarth Reddy, William C. Blackwelder et al. · The Lancet · 2021 · 358 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Burden of dengue infection in India, 2017: a cross-sectional population based serosurvey

Manoj Murhekar, P Kamaraj, Muthusamy Santhosh Kumar et al. · The Lancet Global Health · 2019 · 143 citations · Full text

Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

Pragya D. Yadav, Gajanan Sapkal, Priya Abraham et al. · 2021 · 137 citations · Full text

Investigation B.1.617, Viral Diagnostics, Immunology +21